AdvisorShares Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| DEFINIUM THERAPEUTICS INCDFTX | 12.85% | $5.71M | 121,381 |
| COMPASS PATHWAYS PLCCMPS | 11.45% | $5.09M | 359,647 |
| ATAIBECKLEY INC | 10.47% | $4.65M | 882,892 |
| RELMADA THERAPEUTICS INCRLMD | 6.84% | $3.04M | 438,901 |
| NRX PHARMACEUTICALS INCNRXP | 6.07% | $2.70M | 659,018 |
| NEUROCRINE BIOSCIENCES INCNBIX | 4.38% | $1.95M | 11,553 |
| CYBIN INC | 4.35% | $1.93M | 292,711 |
| GH RESEARCH PLC | 4.31% | $1.92M | 71,267 |
| ALKERMES PLC | 4.30% | $1.91M | 36,438 |
| ALTO NEUROSCIENCE INCANRO | 4.20% | $1.87M | 70,748 |
| ABBVIE INCABBV | 4.14% | $1.84M | 7,318 |
| BLACKROCK TREASURY TRUSTCash or money market | 3.97% | $1.76M | 1,763,357 |
| BRIGHT MINDS BIOSCIENCES INCDRUG | 3.84% | $1.70M | 24,274 |
| JOHNSON & JOHNSONJNJ | 3.61% | $1.60M | 6,308 |
| DREY INST PREF GOV MM-MCash or money market | 3.10% | $1.38M | 1,378,957 |
| SUPERNUS PHARMACEUTICALS INCSUPN | 2.89% | $1.28M | 27,618 |
| NEUPHORIA THERAPEUTICS INCNEUP | 2.49% | $1.11M | 252,909 |
| NEURONETICS INCSTIM | 2.17% | $965.63K | 742,795 |
| QUANTUM BIOPHARMA LTDQNTM | 1.66% | $736.90K | 203,564 |
| OPTIMI HEALTH CORPOPTH | 1.18% | $523.22K | 102,794 |
| PASITHEA THERAPEUTICS CORPKTTA | 1.09% | $483.21K | 937,550 |
| SILO PHARMA INCSILO | 1.06% | $469.36K | 75,582 |
| PSYENCE BIOMEDICAL LTDPBM | 0.84% | $373.88K | 122,184 |
| INCANNEX HEALTHCARE INCIXHL | 0.52% | $228.86K | 60,868 |
| NUMINUS WELLNESS INC | 0.47% | $209.08K | 8,482,082 |
| IGC PHARMA INCIGC | 0.42% | $184.55K | 678,480 |
| VISTAGEN THERAPEUTICS INCVTGN | 0.22% | $99.13K | 438,643 |
| ENVERIC BIOSCIENCES INCENVB | 0.11% | $48.88K | 35,417 |
| CLEARMIND MEDICINE INC | 0.01% | $2.57K | 1,169 |
| UNBUZZD WELLNESS INC | 0.00% | $0 | 263,236 |
| SAGE THERAPEUTICS INC | 0.00% | $0 | 89,780 |
| QUANTUM BIOPHARMA | 0.00% | $0 | 46,617 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.